These results, together with previous data in other cancer types, highlight the potential for dual targeting of both PIM kinase and PI3K-mTOR pathways as a promising strategy for the future treatment of patients with PIM kinase and/or PI3K-mTOR activated NSCLC. The gene discussed is PIK3CA; the disease is cancer.